AbbVie ’s VIEKIRAX + EXVIERA receives positive opinion for eight-week treatment of GT1b HCV

AbbVie has received a positive opinion for a shorter, eight-week treatment of VIEKIRAX (ombitasvir / paritaprevir / ritonavir tablets) + EXVIERA (dasabuvir tablets) as an option for previously untreated adult patients with genotype 1b (GT1b) chronic …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Norvir | Pharmaceuticals